세계의 진통제 시장(2023-2030년)
Global Pain Relief Medication Market - 2023-2030
환자 QOL을 향상시키기 위한 진통제에 대한 요구 상승이 예측기간 중 세계의 진통제 시장 성장을 지지하고 있습니다.
The global pain relief medication size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).
Pain is a troubling sensation developed because of tissue injury or disease. Various conditions can induce distress, like abdominal ulcers, sclerosis, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Based on the duration of pain, sensation pain is of two types chronic, lasting for the long term, and acute pain for the short term, which can last for months, weeks, or days. In contrast, chronic pain lasts for years.
The rising need for pain-relieving medication to increase the patient quality of life is boosting the global pain-relief medication market growth during the forecast period.
The growing demand for pain-relieving medication is fueling the market growth globally.
Pain Relief Medications alleviate extreme pain in conditions such as post-surgery pain, a serious physical injury, or pain from cancer. They are also used for other types of long-standing pain. The growing number of postoperative pains, physical traumas and chronic non-communicable diseases such as arthritis and cancer are creating the demand for Pain Relief Medication. For instance, according to the WHO, more than millions suffer non-fatal injuries each year, which lead to hospitalizations or treatment by general practitioners or emergency department and acute care visits and often result in temporary or permanent disability. Also, the International Agency for Research on Cancer WHO assessed there were about 19292789 new cases of different types of cancer globally in 2020. Similarly, according to the Global Rheumatoid Arthritis Network, approximately 350 million people lived with arthritis in 2021. Additionally, the NIH states that over 75% of the patients who have undergone surgery experience acute postoperative pain, which might be medium to high in severity.
Furthermore, the increasing number of surgeries performed globally also expands the global pain relief medication market. For instance, according to the European core health indicators (ECHI), the two most common surgical operations and procedures performed in EU hospitals were cataract surgery and cesarean sections. Cataract surgery was conducted 3.66 million times in 2020 across the EU Member States. At the same time, the cesarean section procedure was performed at least 1.12 million times in the EU in 2020.
The availability and introduction of other pain-relieving treatments is a major hurdle in the market's global growth.
However, the availability and introduction of other pain relieving treatments, such as Transcutaneous Electrical Nerve Stimulation (TENS) therapy, involves using low-voltage electric currents to treat pain. Furthermore, in January 2021, Boston Scientific Corporation introduced the WaveWriter Alpha, a portfolio of Spinal Cord Stimulator (SCS) systems that incorporate treatment choices for personalized pain relief.
COVID-19 Impact Analysis
The COVID-19 pandemic has greatly impacted the global pain relief medication market. Chronic pain management during the coronavirus disease 2019 (COVID-19) pandemic was difficult, particularly with rising proof that COVID-19 infection is associated with myalgias, referred pain, and widespread hyperalgesia. Non-Opioid Analgesic medication used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in addressing mild-to-moderate pain as part of multimodal analgesia, also be utilized safely to relieve symptoms of COVID-19, like fever, headache, and acute or chronic pain, which led to increased demand for pain relief medication and positively impacted the market growth.
The chronic pain type is predicted to hold a large share of the global pain relief medication market during the forecast period (2022-2029).
The chronic pain type is expected to hold most of the market share during the forecasted period. According to the Johns Hopkins Hospital, Chronic pain is long-standing pain that lasts beyond the normal healing period or surfaces along with a chronic health condition, like arthritis, Cancer pain, migraines, cluster headaches and others. Chronic pain may be "appearing" and "disappearing" or continuous. The U.S. spends $3.5 trillion annually on health care, with 90% of that going to chronic conditions, including chronic pain. Moreover, according to an article by The Lancet, Chronic pain exerts an immense individual and financial hindrance, impacting over 30% of individuals worldwide. Also, according to the NIH, Chronic pain is favorably dominant among geriatric adults, associated with substantial suffering, disability, social solitariness, and higher expenditures and burden to health care systems. Thus, the growing geriatric population is contributing to the growth of the chronic pain segment. For example, according to WHO, the geriatric population accounted for 1 billion in 2020 and is predicted to reach 1.4 billion by 2030. Thus the data mentioned above indicate that the chronic pain type will dominate the global pain relief medication market
North America oppresses the global pain relief medication market throughout the forecast period (2022-2029).
Owing to the high number of chronic disease cases and the presence of key market players, the North American pain relief medication market is assessed to grow at a high CAGR in the forecast period (2022-2029). Such as, according to the American cancer society estimations, in 2022, about 1.9 million new cancer cases will be analyzed, and around 609,360 cancer-caused deaths in the United States. Likewise, CDC anticipated that approximately 78 million U.S. adults will live with doctor-diagnosed arthritis in 2040, increasing the demand for the Pain Relief Medication analgesic. Similarly, the major key players holding a larger share of the market are U.S. based, such as Johnson & Johnson, Pfizer Inc., Purdue Pharma, Endo International, Mylan, Impax Laboratories and Indivior, contributing to the dominance of North America over the global Pain Relief Medication market. Therefore from the data mentioned above, it is anticipated that North America will hold most of the global pain relief medication market throughout the forecasted period (2022-2029).
The pain relief medication market is moderately competitive since there is a growing demand for pain relief medication and local and global key players. Some key players are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. These key players hold the market through acquisition, product launches, and collaborations. For instance, in July 2021, Venus Remedies Limited launched a consumer healthcare division that will offer various products for pain management.
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals was founded in 1901 in Jerusalem. It is today among the top 15 pharmaceutical companies worldwide. Teva has over 3600 medicines in its product portfolio, with 37,000 employees working globally and 53 production sites globally.
Teva Pharmaceutical's product portfolio of pain relief medication has: Hydromorphone comes under the family of drugs known as opioid painkillers. It is employed to treat moderate-to-severe pain, such as pain after surgery.
The global pain relief medication market report would provide access to approximately 40 + market data tables, 45 + figures, and in the range of 200 (approximate) pages.
LIST NOT EXHAUSTIVE